App-Quantinova.ai

THERAPEUTIC ΤARGETS AND QUALITY INDICATORS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), DEFINED ACCORDING TO THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS: DATA FROM THE “ATTIKON“ LUPUS COHORT

K. Havatza - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

USE OF HYDROXYCHLOROQUINE AND RISK OF HEART FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS

A. Sorour - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Rheumatoid arthritis

Hydroxychloroquine

UTILIZATION OF HYDROXYCHLOROQUINE AND CORTICOSTEROIDS AMONG LUPUS PATIENTS WITH INCIDENT END-STAGE RENAL DISEASE (ESRD) ONSET: A LONGITUDINAL STUDY USING USRDS REGISTRY

A. R. Broder - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Microvascular complications of diabetes 1

Hydroxychloroquine

WITHDRAWAL OF LOW-DOSE STEROIDS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN REMISSION: PREDICTORS OF FLARES AND DIFFERENCE IN OUTCOMES IN SEROLOGICALLY ACTIVE CLINICALLY QUIESCENT PATIENTS

S. Fasano - European League Against Rheumatism (EULAR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Hydroxychloroquine is Associated with Better Patient and Graft Survival in Kidney Transplant Patients with Lupus Nephritis as Cause of ESRD

T. Singh - American Transplant Congress (ATC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus nephritis

Hydroxychloroquine

Hydroxychloroquine in hand OA; Results of the UK hero trial

S.R. Kingsbury - Osteoarthritis Research Society International (OARSI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Rheumatoid arthritis

Hydroxychloroquine

2020 OA vision: emerging therapeutics on the OA landscape

P. Conaghan - Osteoarthritis Research Society International (OARSI) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoarthritis

Hydroxychloroquine

Hydroxychloroquine Improves Atherosclerosis in SLE

Haitao Niu - American Association of Immunologists (AAI) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Lupus

Hydroxychloroquine

Chloroquine and Hydroxychloroquine Myopathy: Clinical Spectrum and Treatment Outcomes

Elie Naddaf - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Cap myopathy

Hydroxychloroquine

CMV Meningitis associated with Hydroxychloroquine

Nishad Shaheid - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Unanticipated Improvement of Stiff Person Syndrome after severe COVID-19

Toluwalase Tofade - American Academy of Neurology (AAN) , 2021

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Acute lung injury

Hydroxychloroquine

Comparing the Performance of Interferon Gamma Release Assays in Autoimmune Skin Diseases

D. Yan - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Tuberculosis

Hydroxychloroquine

A PATIENT-SPECIFIC RE-ENGINEERED CARDIOMYOCYTE MODEL CONFIRMS THE CIRCUMSTANCE-DEPENDENT ARRHYTHMIA RISK ASSOCIATED WITH THE AFRICAN-SPECIFIC COMMON SCN5A POLYMORPHISM (P.SER1103TYR): IMPLICATIONS FOR THE INCREASED SUDDEN DEATHS OBSERVED IN BLACKS DURING THE COVID-19 PANDEMIC

Santha Hamrick - Heart Rhythm Society (HRS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Arrhythmia

Hydroxychloroquine

Covid-19 Reinfection in a Kidney Transplant Patient

Z. Saeed Zafar - American Transplant Congress (ATC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Other

Acute cellular rejection

Hydroxychloroquine

Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).

Rishi Surana - American Society of Clinical Oncology (ASCO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Metastatic pancreatic adenocarcinoma

Hydroxychloroquine

A phase II study investigating biological effects of maintenance usage of hydroxychloroquine on Par-4 levels in patients with resected tumors.

Peng Wang - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Hydroxychloroquine

Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).

Akshara Singareeka Raghavendra - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Hydroxychloroquine

INTENSIVE: InterNaTional rEgistry oN Sars-cov-2 posItiVe nEuroendocrine neoplasm patients.

Francesca Spada - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroendocrine tumors

Hydroxychloroquine

Phase I trial of regorafenib, hydroxychloroquine, and entinostat in metastatic colorectal cancer.

Timothy J Brown - American Society of Clinical Oncology (ASCO) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Hydroxychloroquine

Cerebral Calcifications in Systemic Lupus Erythematosus

Rishika Singh - American Academy of Neurology (AAN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Filters

1151 Abstracts